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PThe ARBITER 6-HALTS Trial
(Arterial Biology for the Investigation of the
Treatment Effects of Reducing Cholesterol 6–
HDL and LDL Treatment Strategies in Atherosclerosis)
Final Results and the Impact of
Medication Adherence, Dose, and Treatment Duration
Todd C. Villines, MD,* Eric J. Stanek, PHARMD,† Patrick J. Devine, MD,* Mark Turco, MD,‡
Michael Miller, MD,§ Neil J. Weissman, MD, Len Griffen, MD,¶ Allen J. Taylor, MD*
Washington, DC; Franklin Lakes, New Jersey; and Takoma Park, Baltimore, and Rockville, Maryland
Objectives This report describes the final results of the ARBITER 6-HALTS (Arterial Biology for the Investigation of the Treat-
ment Effects of Reducing Cholesterol 6–HDL and LDL Treatment Strategies in Atherosclerosis) trial.
Background The ARBITER 6-HALTS trial was terminated early on the basis of a pre-specified interim analysis showing superi-
ority of niacin over ezetimibe on change in carotid intima-media thickness (CIMT). After termination, an addi-
tional 107 subjects completed a close-out assessment.
Methods Patients with coronary heart disease (CHD) or CHD equivalent with low-density lipoprotein cholesterol 100
mg/dl and high-density lipoprotein cholesterol 50 mg/dl for men or 55 mg/dl for women while receiving sta-
ble statin treatment were randomly assigned to ezetimibe (10 mg/day) or extended-release niacin (target dose,
2,000 mg/day). The primary end point was change in mean CIMT, analyzed according to a last observation car-
ried forward method. The relationships of study medication adherence, dosage, and cumulative exposure (prod-
uct of adherence, dose, and time) with change in CIMT were explored.
Results Results in 315 patients included 208 with 14-month follow-up and 107 after mean treatment of 7  3 months.
Niacin (n  154) resulted in significant reduction (regression) in mean CIMT (0.0102  0.0026 mm; p 
0.001) and maximal CIMT (0.0124  0.0036 mm; p  0.001), whereas ezetimibe (n  161) did not reduce
mean CIMT (0.0016  0.0024 mm; p  0.88) or maximal CIMT (0.0005  0.0029 mm; p  0.88) com-
pared with baseline. There was a significant difference between ezetimibe and niacin treatment groups on mean
changes in CIMT, favoring niacin, for both mean CIMT (p  0.016) and maximal CIMT (p  0.01). Increased cu-
mulative drug exposure was related to regression of CIMT with niacin, and progression of CIMT with ezetimibe.
Conclusions Niacin induces regression of CIMT and is superior to ezetimibe for patients taking statins. (Comparative Study of
the Effect of Ezetimibe Versus Extended-Release Niacin on Atherosclerosis; NCT00397657) (J Am Coll Cardiol
2010;55:2721–6) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.03.017o
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ucted a comparative-efficacy trial examining the addition
rom the *Cardiology Service, Walter Reed Army Medical Center, Washington, DC;
Medco Health Solutions, Franklin Lakes, New Jersey; ‡Washington Adventist Hospi-
al, Takoma Park, Maryland; §University of Maryland Medical Center, Baltimore,
aryland; Medstar Research Institute, Washington Hospital Center, Washington,
C; and ¶Cardiac Associates, Rockville, Maryland. Abbott Pharmaceuticals funded
he study by an unrestricted, investigator-initiated research grant administered by the
enry M. Jackson Foundation for the Advancement of Military Medicine, Rockville,
aryland. Dr. Villines has received lecture honoraria from Novartis Pharmaceuticals. Dr. 2f ezetimibe or extended-release niacin (ERN) on carotid
ntima-media thickness (CIMT) in high-risk patients on
table, chronic statin monotherapy (2). Results within the
nitial 208 patients completing the 14-month trial demon-
tanek is an employee, with significant equity holdings, of Medco Health Solutions Inc.
r. Miller has received speaking honoraria from Merck. Dr. Turco received consulting
ees and lecture honoraria from Abbott Cardiovascular. Dr. Taylor receives lecture
onoraria from Abbott that are donated to charity. The opinions or assertions herein are
he private views of the authors and are not to be construed as reflecting the views of the
epartment of the Army or the Department of Defense.
Manuscript received January 15, 2010; revised manuscript received February 26,
010, accepted March 12, 2010.
MP
r
d
p
c
e
c
(
l

d
t
d
t
t
d
t
t
b
a
B
u
m
p
I
d
c
o
A
e
S
v
v
g
W
p
t
s
s
s
o
d
m
s
a
F
d
h
2
2
e
fi
t
e
c
C
r
m
(
u
t
p
a
l
s
m
p
R
T
t
A
(
s
6
b
p
t
d
i
l
1
t
l
p
2722 Villines et al. JACC Vol. 55, No. 24, 2010
The ARBITER 6-HALTS Trial Final Results June 15, 2010:2721–6strated superiority of ERN over
ezetimibe in the change in CIMT,
and the trial was stopped early in
a pre-specified interim analysis
(3). Herein, we extend our initial
report with results on final CIMT
imaging among all patients enrolled
in the ARBITER 6-HALTS (Ar-
terial Biology for the Investigation
of the Treatment Effects of Re-
ducing Cholesterol 6–HDL and
LDL Treatment Strategies) trial.
These results include an analysis of
the last-observed CIMT assess-
ment for the full trial sample, and
the effect on CIMT of study med-
ication adherence, dose optimiza-
tion, and treatment duration.
ethods
atient population. The rationale, design, and primary
esults of the ARBITER 6-HALTS study have been
escribed (2,3). Briefly, inclusion criteria were as follows: 1)
atients at least 30 years of age with known atherosclerotic
ardiovascular disease or coronary heart disease (CHD)
quivalent; 2) currently taking statin monotherapy at a
onsistent dose; 3) low-density lipoprotein cholesterol
LDL-C) 100 mg/dl (2.6 mmol/l); and 4) high-density
ipoprotein cholesterol (HDL-C) 50 mg/dl in men or
55 mg/dl in women (1.3 or 1.4 mmol/l, respectively),
ocumented on a lipid panel within 3 months of enrollment.
Eligible patients were randomly assigned to open-label
herapy with either ezetimibe (10 mg/day) or ERN (target
ose 2,000 mg/day). The ERN was initiated at 500 mg/day
aken at bedtime, and increased by 500 mg every other week
o the maximum tolerated dose. There were no protocol-
irected changes in statin medications or dosage throughout
he study. Adherence to study medication was determined
hrough tablet counts. The primary end point was the
etween-group difference in the change in mean CIMT
fter 14 months.
-mode ultrasonography of the carotid arteries. Carotid
ltrasound examinations were performed at baseline, 8
onths, and 14 months. We have previously described the
rotocol for CIMT assessment utilized in this study (2,3).
n summary, mean and maximal diastolic CIMT of the
istal 1 cm of the far wall of the right and left common
arotid arteries was measured by a single, blinded, trained
bserver utilizing an automated border-detection algorithm.
ll images were obtained in duplicate, and no scans were
xcluded on the basis of image quality.
tatistical analysis. Between-group data for continuous
ariables were evaluated using a t test for independent
ariables or a Mann-Whitney U test, as appropriate. Cate-
Abbreviations
and Acronyms
CHD  coronary heart
disease
CI  confidence interval
CIMT  carotid intima-
media thickness
ERN  extended-release
niacin
HDL-C  high-density
lipoprotein cholesterol
hsCRP  highly-sensitive
C-reactive protein
IQR  interquartile range
LDL-C  low-density
lipoprotein cholesterolorical variables were evaluated using the chi-square test. iithin-group comparisons of continuous variables were
erformed using a paired t test or Wilcoxon signed-rank
est, as appropriate. A 2-sided p value0.05 was considered
tatistically significant. The SPSS for Windows version 16
oftware (SPSS Inc., Chicago, Illinois) was used for all
tatistical analyses. On the basis of a minimum sample size
f 150 per group, the trial had an 80% power to detect a
ifference of CIMT change between agents of 0.02  0.06
m/year (  0.05).
As previously described (2,3), the study design pre-
pecified the performance of a blinded, interim analysis
ccording to the conservative method of O’Brien and
leming (4) with an alpha spending function, to be con-
ucted after 180 subjects (60% of the planned sample size)
ad completed the trial. After the interim analysis (March
009), an independent data advisory committee (June 4,
009) evaluated the primary end point data without knowl-
dge of treatment assignment, and based upon the trial
ndings, unanimously recommended that the trial should be
erminated.
After study termination on June 4, 2009, all actively
nrolled patients were contacted and returned for final
ollection of clinical variables, laboratory data, and blinded
IMT assessment. Among the 363 patients initially en-
olled in the trial, 208 patients had completed the entire 14
onths of the study period at the time of their final visit
111 ezetimibe, 97 ERN), and 44 had left the study. Final
ltrasound examinations could not be obtained in 4 addi-
ional subjects after termination of the study (total of 48
articipants dropped out), leaving 315 patients for this
nalysis. In 107 of the 315 patients analyzed, final achieved
ipid values and CIMT measurements were performed after
tudy termination at a mean treatment duration of 7  3
onths, and these values are included in the primary end
oint (a last observation carried forward analysis).
esults
he baseline characteristics of the 363 patients enrolled in
he trial were similar between the 2 treatment groups (Table 1).
majority of the patients were male (80%), hypertensive
87%), age 65  11 years, and had taken a statin (atorva-
tatin or simvastatin by 95%) at a mean dose of 42 mg for
 5 years. There was no difference with respect to age,
aseline lipid values, and CIMT between the 48 partici-
ants who did not complete the trial and the remainder of
he trial participants. In addition, there was no significant
ifference among baseline covariates, including demograph-
cs, blood pressure, lipid levels, baseline therapies, or base-
ine CIMT between patients who completed the entire
4-month trial (n  208) and patients who completed the
rial after study termination (n  107). Baseline and final
ipid and biomarker values in the 315 patients who com-
leted the trial are shown in Table 2. Significant reductions
n baseline LDL-C and triglycerides were seen with both
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June 15, 2010:2721–6 The ARBITER 6-HALTS Trial Final Resultszetimibe and ERN. As compared with ERN, patients
reated with ezetimibe achieved significantly lower total
holesterol, LDL-C, and HDL-C, and had higher triglyc-
ride values. There was no difference in baseline or final
asting glucose values between the study groups. There was
o significant difference between groups in clinically di-
ected changes in the statin drug or dose during the study.
ean study drug adherence rates over the duration of the
tudy exceeded 80% in each arm, and were significantly
igher with ezetimibe as compared with ERN (87.5 
5.3% vs. 82.1  17.2%, respectively; p  0.005).
rimary end point. The primary end point was assessed
mong all randomized subjects (n  315) who completed a
nal CIMT measurement after either 14 months (n  208)
r after14 months of treatment (n 107) among subjects
ho had not yet completed the study at the time of its
ermination (Table 3). Treatment with niacin (n  154)
esulted in significant reduction (regression) in mean CIMT
0.0102  0.0026 mm; p  0.001) and maximal CIMT
Baseline Characteristics of 363 PatientsR ndomly Assign d to Ezetimibe or Extended-ReTable 1 B seline Characteristics of 363 PaRandomly Assigned to Ezetimibe or
Male
Age, yrs
Diabetes mellitus
Hypertension
Tobacco use
Family history of CHD
History of coronary heart disease
Angina with documented ischemia
Angiographic coronary disease
Myocardial infarction
Percutaneous coronary revascularization
Coronary bypass surgery
Medications
Beta-blocker
Aspirin
Clopidogrel
ACE inhibitor
Statin therapy
Simvastatin
Atorvastatin
Pravastatin
Rosuvastatin
Lovastatin
Mean daily statin dose, mg
Duration of statin use, yrs
BMI, kg/m2 3
Waist circumference, inches 4
Systolic blood pressure, mm Hg 1
Diastolic blood pressure, mm Hg
CIMT mean thickness, mm 0.89
CIMT maximal thickness, mm 1.00
Values are n (%) or mean  SD.
ACE  angiotensin-converting enzyme; BMI  body mass index; CH0.0124  0.0036 mm; p  0.001) compared to baseline. dreatment with ezetimibe (n  161) had no effect on mean
IMT (0.0016  0.0024 mm; p  0.88) or maximal
IMT (0.0005  0.0029 mm; p  0.88) compared to
aseline. There was a significant difference between the
zetimibe and niacin treatment groups on the change in
IMT, favoring niacin for both mean CIMT (p  0.016)
nd maximal CIMT (p  0.01) among the 315 patients
ompleting the trial. Imputing baseline CIMT as the final
IMT (last observation of baseline CIMT carried forward)
n the 48 patients who did not complete the trial resulted in
o change in the primary outcome.
mpact of cumulative drug exposure. Based on differences
n study medication adherence, ERN dosage achieved and
reatment duration (due to early trial termination) between
rial participants, we performed an exploratory analysis to
ssess the impact of these variables on change in CIMT
mong niacin and ezetimibe treatment groups. The product
f study drug adherence, dosage, and treatment duration
as calculated to estimate cumulative exposure to study
e Niacin
nded-Release Niacin
ibe
76)
Niacin
(n  187) p Value
1.8) 147 (78.6) 0.44
11 65 10 0.63
0.9) 73 (39.0) 0.71
7.5) 163 (87.2) 0.92
.1) 13 (7.0) 0.68
6.9) 88 (47.3) 0.05
6.9) 58 (31.2) 0.25
1.9) 116 (62.0) 0.98
3.5) 54 (28.9) 0.34
9.8) 58 (31.0) 0.08
5.0) 48 (25.7) 0.88
1.0) 125 (67.6) 0.48
3.8) 176 (94.1) 0.88
4.8) 30 (27.0) 0.70
6.8) 96 (51.9) 0.35
9.8) 78 (41.7) 0.18
4.5) 88 (47.1) 0.22
.8) 9 (4.8)
.8) 8 (4.3)
) 4 (2.1)
24 42 24 0.95
5.6 6.1 4.9 0.40
5.6 31.3 6.4 0.43
5.0 41.6 5.9 0.27
18 134 18 0.08
10 75 11 0.82
0.1484 0.9001 0.1558 0.83
0.1548 1.0092 0.1650 0.90
ronary heart disease; CIMT  carotid intima-media thickness.leasti nts
Exte
Ezetim
(n  1
144 (8
65
72 (4
154 (8
9 (5
65 (3
65 (3
109 (6
59 (3
70 (3
44 (2
125 (7
165 (9
32 (2
100 (5
70 (3
96 (5
5 (2
5 (2
0 (0
42
6.5
0.8
0.9
37
74
57
65rug as an integrated measure of drug effect (5). The
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The ARBITER 6-HALTS Trial Final Results June 15, 2010:2721–6elationships between increasing cumulative drug exposure
lowest, quartile 1 to highest, quartile 4) and change in
ean CIMT for all subjects using the method of last
bservation carried forward are shown in Table 4 and Figure 1.
ncreased cumulative drug exposure resulted in regression of
IMT with niacin, and progression of CIMT with
zetimibe. Specifically, comparing participants treated op-
imally (best-case comparison), defined as those with the
ighest quartile of study drug adherence and those reaching
he target 2,000 mg/day in the niacin group (quartile 4) for
he entire 14 months of the study, patients treated with
RN had significant reduction (regression) of mean CIMT
rom baseline (0.0128  0.0078 mm), whereas patients
reated with ezetimibe experienced CIMT progression
0.0067  0.0059 mm).
erum Biomarkers at Baseline and Study CompletionTable 2 Serum Biomarkers at Baseline and Study Completion
Baseline (n 
Ezetimibe
(n  161)
Total cholesterol, mg/dl 147.3 28.5
p value, between groups 0.96
p value, change from baseline
HDL-C, mg/dl 43.0 8.8
p value, between groups 0.32
p value, change from baseline
LDL-C, mg/dl 84.5 23.8
p value, between groups 0.59
p value, change from baseline
Triglycerides, mg/dl 118 (87–160)
p value, between groups 0.24
p value, change from baseline
Fasting glucose, mg/dl 104.0 27.1
p value, between groups 0.97
p value, change from baseline
hsCRP, mg/l 1.6 (0.7–3.2)
p value, between groups 0.71
p value, change from baseline
alues are mean  SD or median (interquartile range).
HDL-C  high-density lipoprotein cholesterol; hsCRP  highly-sensitive C-reactive protein; LDL-C
Change From Baseline CIMT by Treatment Grouand for All Subjects With the Last Observation CTable 3 Ch nge From Baseline CIMT by Treand for All Subjects With the Last O
CIMT Ezetimibe
Completing subjects (n  111)
Mean thickness, mm 0.0007 0.003
p value, change from baseline 0.84
Maximal thickness, mm 0.0009 0.003
p value, change from baseline 0.81
Last observation carried forward (n  161)
Mean thickness, mm 0.0016 0.002
p value, change from baseline 0.52
Maximal thickness, mm 0.0005 0.002
p value, change from baseline 0.88Data shown as mean  SE.
CIMT  carotid intima-media thickness.iscussion
e recently demonstrated that ERN leads to significant
egression of CIMT and was superior to ezetimibe when
dded to chronic statin therapy among 208 high-risk
atients who had completed 14 months of randomized,
pen-label, parallel group treatment in the ARBITER 6-
ALTS trial (3). This comparative-efficacy trial was
topped before all enrolled patients completing the intended
4 months of drug treatment after a planned interim
nalysis clearly demonstrated the superiority of ERN over
zetimibe in the effect on CIMT. In the current analysis, we
xtend our original observations by examining the effect of
he study treatments on CIMT within a last observation
arried forward and therapy optimization analysis.
Final Values (n  315)
Niacin
(n  154)
Ezetimibe
(n  161)
Niacin
(n  154)
47.2 24.8 127.5 24.8 137.6 30.5
0.002
0.001 0.001
42.0 8.3 41.1 8.5 49.7 11.5
0.001
0.001 0.001
83.2 19.4 65.5 20.0 72.7 25.9
0.007
0.001 0.001
29 (89–166) 111 (82–144) 91 (69–134)
0.012
0.025 0.001
03.9 29.2 111.2 33.8 111.5 41.0
0.96
0.03 0.001
.3 (0.8–3.7) 1.0 (0.5–2.9) 1.0 (0.4–2.3)
0.21
0.001 0.06
-density lipoprotein cholesterol.
Completing Subjectsd Forwardnt Group for Completing Subjects
vation Carried Forward
Niacin p Value (Ezetimibe vs. Niacin)
(n  97)
0.0142 0.0041 0.01
0.001
0.0181 0.0050 0.006
0.001
(n  154)
0.0102 0.0026 0.016
0.001
0.0124 0.0036 0.01
0.001315)
1
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June 15, 2010:2721–6 The ARBITER 6-HALTS Trial Final ResultsConsistent with the results seen for patients completing
4 months of treatment, among the entire study group (n
15) including 208 subjects treated for the full study
uration and 107 subjects treated for a mean of 7 months,
herapy with ERN led to significant regression of baseline
IMT among statin-treated patients with an LDL-C
100 mg/dl and an HDL-C 50 or 55 mg/dl. Treatment
ith ezetimibe did not significantly change CIMT. Com-
aratively, there was a significant difference between the
ffect of niacin and ezetimibe on changes in CIMT,
avoring niacin. These results strengthen the findings from
he interim analysis through the inclusion of patients treated
or shorter times (last observation carried forward analysis),
hich might have been expected to reduce the magnitude of
hange From Baseline CIMT Stratified by Quartiles of Increasing CTable 4 Change From Baseline CIMT Stratified by Quartiles of
Quartile 1
Ezetimibe
Adherence, % 71 22
Maximum dose, mg/day 9 2
Treatment duration, months 6.9 2.6
Change in mean CIMT, mm 0.0071 0.0031 0
Niacin
Adherence, % 63 19
Maximum dose, mg/day 1271 690
Treatment duration, months 8.2 4.1
Change in mean CIMT, mm 0.0052 0.0041 0
CIMT p value, ezetimibe vs. niacin within quartile 0.71
Cumulative drug exposure  (adherence  dose  treatment duration). Adherence, dose, and t
ANOVA  analysis of variance; CIMT  carotid intima-media thickness.
Figure 1 Relationship Between Quartiles of Cumulative Drug Ex
Cumulative drug exposure was calculated as the product of mean study drug adhe
sure (lowest, quartile 1, to highest, quartile 4) and change in mean carotid intima-
forward is shown. The relationship between quartiles of cumulative drug exposure
[ANOVA] p  0.05), and niacin (red line) (ANOVA p  0.23).ffect between the 2 treatment strategies originally observed.
his is a noteworthy possibility within the trial design of
RBITER 6-HALTS with an 8-week titration period for
RN to the target dose of 2,000 mg/day, as opposed to
zetimibe, which was initiated at the maximal clinical dose.
inal results confirm the difference in the primary outcome
nd preserved magnitude of CIMT regression among pa-
ients taking ERN. In addition, the magnitude of effect of
RN on mean CIMT, producing regression (0.0142 
.0041 mm), over 14 months of treatment in the relatively
igh risk ARBITER 6-HALTS study population is note-
orthy in comparison with other contemporaneous lipid-
owering trials using similar CIMT methodology. In the
ETEOR (Measuring Effects of Intima-Media Thickness:
ative Drug Exposure* to Ezetimibe and Niacinasing Cumulative Drug Exposure* to Ezetimibe and Niacin
ile 2 Quartile 3 Quartile 4 ANOVA p Value
 8 94 1 98 1 0.001
0 10 10
 1.4 14 14 0.001
 0.0036 0.0009 0.0067 0.0067 0.0059 0.05
 14 87 6 98 1 0.001
 441 2,000 2,000 0.001
 2.7 13.8 0.7 14 0.001
 0.0027 0.0148 0.0060 0.0128 0.0078 0.23
3 0.13 0.048
nt duration expressed as mean  SD; CIMT expressed as mean  SE.
re to Ezetimibe and Niacin and Change in CIMT
dose, and time in the study. The relationship between quartiles of drug expo-
thickness (CIMT) for all subjects using the method of last observation carried
ange in CIMT is shown separately for ezetimibe (blue line) (analysis of varianceumulIncre
Quart
87
1
13.2
.0051
80
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The ARBITER 6-HALTS Trial Final Results June 15, 2010:2721–6n Evaluation of Rosuvastatin) trial, treatment for 24
onths with high-potency statin monotherapy (rosuvastatin
0 mg; mean final LDL 78 mg/dl) in a low-risk population
esulted in a change in mean common CIMT of 0.0004 mm
95% confidence interval: 0.0011 to 0.0019 mm), as
ompared to placebo 0.0088 mm (95% confidence interval:
.0064 to 0.0112 mm) (6).
The observation that the CIMT response was related to
iacin adherence, dose, and increased treatment duration,
alculated as cumulative drug exposure, is consistent with a
rug effect as shown in prior studies demonstrating a
avorable impact of niacin on clinical events and atheroscle-
osis (7–9). A prior study has shown regression of CIMT
hen ERN adherence rates are high, even when the dose
as2,000 mg/day (8,9). Additional studies examining the
ptimal and minimal effective dose of ERN on atheroscle-
osis, and ultimately clinical events, are warranted.
The relationship between cumulative drug exposure and
he CIMT effect of ERN supports an expected, direct
elationship between increasing intensity of drug exposure
through a composite of dose, adherence, and time) and its
ffect on atherosclerosis. In contrast, findings with
zetimibe showing an unexpected inverse relationship be-
ween intensity of drug exposure and CIMT draw further
ttention to a growing body of evidence on the diverse
ffects of ezetimibe on cholesterol transport mechanisms,
uch as interference with the pivotal HDL receptors SRB-1,
nd ABCA1 (10,11). Although the net health impact of
zetimibe’s described off-target receptor effects are yet to be
ully understood, this evolving science clearly indicates that
he pharmacologic effects of ezetimibe extend beyond the
imple inhibition of enteric cholesterol absorption, and
eduction of LDL-C.
tudy limitations. A limitation of this study is the use of
IMT as a surrogate for clinical end points. While the
reponderance of studies demonstrate the validity of CIMT
s a surrogate for cardiovascular events (3,12–14), the
ltimate net health impact of therapeutics requires clinical
nd point trials. Additionally, our analysis evaluating cumu-
ative drug exposure is post-hoc and exploratory in nature.
ample size is limited within ERN subjects who did not
chieve the 2,000 mg/day target dose, and such subjects also
ere less adherent to the therapy. Prior studies in highly
dherent subjects treated for 1 to 2 years at the 1,000
g/day dose showed regression of CIMT (8,9). Dose-
anging studies would be useful to further elucidate dose
esponse effects of ERN on CIMT.
onclusions
inal results from the ARBITER 6-HALTS trial confirm
he superiority of extended-release niacin over ezetimibe for Khe end point of change in CIMT and the ability of niacin
o induce CIMT regression. Increased cumulative drug
xposure was related to regression of CIMT with niacin,
nd progression of CIMT with ezetimibe.
eprint requests and correspondence: Dr. Todd C. Villines,
ardiology Service, Walter Reed Army Medical Center, 6900
eorgia Avenue, NW, Building 2, Room 4A-34A, Washington,
C 20307. E-mail: todd.villines@amedd.army.mil.
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